Abstracts tagged "5-HT"

Abstract Number: 1769 • 2019 ACR/ARP Annual Meeting
Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response
Unnikrishnan M Chandrasekharan¹, Jennifer Harvey ², Mackenzie Dunlap ², Marcia Leon Rabanal ², Vandana Rai ² and M. Elaine Husni ³, ¹Cleveland clinic foundation, Cleveland, OH, ²Cleveland clinic, Cleveland, ³Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Background/Purpose:Anti-TNF agents have revolutionized the clinical outcomes of patients with rheumatoid and psoriatic diseases. However, up to 40% of patients do not respond or…
Abstract Number: 1857 • 2016 ACR/ARHP Annual Meeting
A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Christina Wenglén¹, Lars Pettersson², Helena Arozenius² and Gunilla Ekström¹, ¹R&D, AnaMar AB, Lund, Sweden, ²AnaMar AB, Lund, Sweden
Background/Purpose: Methods: Results: Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates…
Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting
Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Bruce Daugherty, Leland Gershell and Seth Lederman, Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].